A person receives subcutaneous immunotherapy as an injection under the skin. This treatment method has shown similar effectiveness to intravenous (IV) infusions that healthcare professionals often use ...
Trial Supports Subcutaneous Isatuximab as Effective Alternative to IV Version: Xavier Leleu, MD, PhD
The phase 3 IRAKLIA trial found that subcutaneous isatuximab delivered via an on-body system was as effective and safe as intravenous (IV) administration in relapsed/refractory multiple myeloma, ...
Subcutaneous immunotherapy for cancer can cause many of the same side effects as intravenous (IV) immunotherapy because it involves the same medications. Injection site reactions are a common but ...
A 40-year-old woman with type 1 diabetes mellitus (T1DM) who injected insulin into her abdomen developed a firm subcutaneous mass in the right lower quadrant. Pathology after surgical excision showed ...
The efficacy of adoptive T-cell therapies based on chimaeric antigen receptors (CARs) is limited by the poor proliferation and persistence of the engineered T cells. Here we show that a subcutaneously ...
The Chosun Ilbo on MSN
MSD's Keytruda subcutaneous form approved, marking 1-minute anticancer drug era
A subcutaneous (SC) immune anticancer drug that can be administered in 1–2 minutes by injection into the skin has been newly approved in South Korea. MSD’s immune anticancer drug ‘Keytruda’, widely ...
By imaging fluorescence from the small luciferase Nanoluc, Keselowsky and co-authors show that Nanoluc–Gal3 at the subcutaneous injection site in mice was locally retained, whereas unanchored Nanoluc ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results